Knockdown of RHPN1-AS1 was shown to result in the development of gefitinib resistance in non-small cell lung cancer cells, whereas the overexpression of RHPN1-AS1 sensitized gefitinib resistant NSCLC cells to gefitinib treatment. The gene discussed is RHPN1; the disease is non-small cell lung carcinoma.